Results 141 to 150 of about 21,829 (156)

Erratum for Li et al., "Pharmacokinetics/pharmacodynamics of ceftazidime-avibactam in critically ill adult patients receiving continuous renal replacement therapy". [PDF]

Antimicrob Agents Chemother
Li C, Wang Y, Chen F, Huang L, Dong J, Fan W, Yue H, Ge Y.   +7 more
europepmc   +1 more source

Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam. [PDF]

BMC Genom Data
Wan Y, Wong JLC, Sanchez-Garrido J, Low WW, Turton JF, Morecchiato F, Baccani I, Dodgson K, Rossolini GM, Woodford N, Frankel G, Jauneikaite E, Meunier D, Hopkins KL.   +13 more
europepmc   +1 more source

Real-world usage, effectiveness, and microbiological features of ceftazidime-avibactam in clinical practice in China. [PDF]

Front Cell Infect Microbiol
Qin X, Xiang T, Zhang X, Ma X, Zhao W, Yu Y, Zhao C, Gao L, Li L, Wang T, Pang C, Zhao X, Han R, Cao F, Su M, Lu J, Xu W, Yin S, Lu D, Yang X, Wang M.   +20 more
europepmc   +1 more source

Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers. [PDF]

Antimicrob Agents Chemother
Kunz Coyne AJ, Judd C, Lucas K, Al Musawa M, Van Helden S, Holger D, Althubyani A, Yost C, VanDorf S, Mynatt R, Kufel WD, Hayes J, Deri CR, Wrenn RH, Slaton CN, Morrisette T, Davis M, Cabanilla MG, Shald E, White BP, Sassine J, Truong J, Rosenberg J, Andrade J, Cerenzio J, Medvedeva N, Ha D, Eubank TA, Garey KW, Biagi M, Todd M, Kang-Birken SL, Rux C, Molina KC, Jankowski CA, Claeys KC, Venugopalan V, Veve MP, Orzol C, Eshaya M, Caniff KE, Bleick C, Rybak MJ.   +42 more
europepmc   +1 more source

Combination Therapy with Ceftazidime-Avibactam, Aztreonam, and Topical Polymyxin B for NDM-Producing <i>Klebsiella pneumoniae</i> CNS Infection: A Case Report. [PDF]

Infect Drug Resist
Qi G, Cong W, Zhang M, Wang S, Bai Z, Li B, Chen H.   +6 more
europepmc   +1 more source

Prevalence, Antimicrobial Susceptibility, and Molecular Characteristics of Ceftazidime-Avibactam-Resistant <i>Klebsiella pneumoniae</i> in a Chinese Hospital. [PDF]

Infect Drug Resist
Li J, Wang H, Liu Z, Xia Y, Hu Y, Wang H, Xia F, Zou M.   +7 more
europepmc   +1 more source

PK/PD-guided ceftazidime-avibactam dosing for multidrug-resistant <i>Pseudomonas aeruginosa</i> infection in a preterm infant with chylothorax and ascites: a case report. [PDF]

Front Pharmacol
Yuan W, Zhao X, Liu X, Tao X, Zeng L.
europepmc   +1 more source

KPC-33 and ompK37 mutations: Unraveling the mechanism of ceftazidime/avibactam resistance in ST11 carbapenem-resistant Klebsiella pneumoniae. [PDF]

PLoS One
Zhao S, Ye L, Song S, Sun J, Xu J, Jiang F, Kang H.   +6 more
europepmc   +1 more source

Intrapulmonary penetration of ceftolozane/tazobactam and ceftazidime/avibactam administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. [PDF]

Crit Care
Benítez-Cano A, Sancho-Araiz A, Carazo J, Ramos I, Sánchez-Font A, Chalela R, López-Palacio M, García-Prieto FF, Navarrete-Rouco ME, Juanes-Borrego AM, Gómez-Junyent J, Horcajada JP, Adalia R, Roberts J, Sorlí L, Luque S.   +15 more
europepmc   +1 more source